{"id":836075,"date":"2025-04-10T09:22:59","date_gmt":"2025-04-10T13:22:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\/"},"modified":"2025-04-10T09:22:59","modified_gmt":"2025-04-10T13:22:59","slug":"sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\/","title":{"rendered":"SAGE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. (NASDAQ: SAGE) and Encourages Long-Term SAGE Investors to Contact the Firm"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">PHILADELPHIA, April  10, 2025  (GLOBE NEWSWIRE) &#8212; Kaskela Law LLC announces that it is investigating Sage Therapeutics, Inc. (NASDAQ: SAGE) (\u201cSage\u201d) on behalf of the company\u2019s long-term investors.<\/p>\n<p align=\"left\">\n        <strong><br \/>\n          <em>Click here for additional information: <\/em><br \/>\n        <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=U-EanwdDPByJLk53Hgj2xA7LZjSvogH4sHbuAIvabf1Zw4hW3roxSPR2MJUrU4dsHL9eH6Enwt6JaK61neBE5HK8k3wxQU2ChIqLmT-iioed6MhRUViONJMNsKt4ZCS9t0V3SJ32ekTlJH6YBJHjEoqR8YtGwJGHQ0lBNwDAW9w=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <em>https:\/\/kaskelalaw.com\/case\/sage-therapeutics\/<\/em><br \/>\n          <\/strong><br \/>\n        <\/a>\n      <\/p>\n<p align=\"left\">Recently a securities fraud complaint was filed against Sage on behalf of certain investors who purchased or acquired shares of the company\u2019s stock between April 12, 2021 and July 23, 2024 (the \u201cClass Period\u201d).<\/p>\n<p align=\"left\">According to the complaint, during the Class Period, Sage and certain of the company\u2019s senior executive officers concealed adverse information and substantial risks associated with Sage\u2019s development of three pharmaceuticals: (i) zuranolone (SAGE-217\/BIIB125), a flagship drug, then under development in collaboration with affiliates of Biogen Inc. (together, \u201cBiogen\u201d), whose most lucrative potential application was to treat major depressive disorder (\u201cMDD\u201d); (ii) SAGE-718 (dalzanemdor), for the treatment of certain cognitive disorders and diseases; and (iii) SAGE-324 (BIIB124), under development with Biogen, for the treatment of essential tremor.<\/p>\n<p align=\"left\">As further detailed in the complaint, by the end of the Class Period, investors learned that the FDA had denied approval of zuranolone for the treatment of MDD because it lacked long-term efficacy and was no better than a placebo after only weeks\u2014a drug profile inconsistent with FDA guidance from 2018 for developing a lasting and effective MDD treatment. Investors also learned that in approving zuranolone for PPD but not MDD, the FDA emphasized that clinical testing seemed to correlate zuranolone with an increased incidence of suicidal ideation and behavior in MDD patients that was not present for PPD patients. Investors were also shocked to learn that Sage abandoned developing SAGE-718 and SAGE-324 due to adverse clinical trials, resulting in Biogen\u2019s decision to terminate its collaboration and license agreement with Sage for the development of SAGE-324. In response to these disclosures, shares of Sage\u2019s common stock significantly declined in value, harming the company\u2019s long-term investors.<\/p>\n<p align=\"left\">The investigation seeks to determine whether the members of Sage\u2019s board of directors violated the securities laws and\/or breached their fiduciary duties in connection with the above alleged misconduct.<\/p>\n<p align=\"left\">\n        <strong><br \/>\n          <em>Sage shareholders who purchased or acquired their KVUE shares <\/em><br \/>\n        <\/strong><br \/>\n        <strong><br \/>\n          <em><br \/>\n            <u>prior to January 1, 2024<\/u><br \/>\n          <\/em><br \/>\n        <\/strong><br \/>\n        <strong><br \/>\n          <em> are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 \u2013 0750 for additional information about this investigation and their legal rights and options. Alternatively, investors may submit their information to the firm by clicking on the following link (or by copying and pasting the link into your browser):<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"left\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=U-EanwdDPByJLk53Hgj2xA7LZjSvogH4sHbuAIvabf1Zw4hW3roxSPR2MJUrU4dsCQUrRR9qdvtAfaRy_7J4YT_rgRqxdYBxVqojcNYnIAhDjRSUZtQGODslf74IShD4hkV5Mpg2yCAfa3pv9JY4i9uMh1ewfGf6jBYygNEk_RQ=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <em>https:\/\/kaskelalaw.com\/case\/sage-therapeutics\/<\/em><br \/>\n          <\/strong><br \/>\n        <\/a>\n      <\/p>\n<p align=\"left\">Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger &amp; acquisition litigation on a contingent basis. For additional information about Kaskela Law LLC please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dVFdqXDzQHW-XC9ZhWFXiA5MzO-ZmL3DPICBQN4cTZttoEvTMkk_2UVqFqwL0Cp0ZQZAOPIfQFaV2GjtArBSwaYUP2df5X_DPDcgX_V8PUE=\" rel=\"nofollow\" target=\"_blank\">www.kaskelalaw.com<\/a>.<\/p>\n<p align=\"left\">\n        <strong>CONTACT:<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>KASKELA LAW LLC<\/strong><br \/>\n        <br \/>D. Seamus Kaskela, Esq.<br \/>(<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tfvuWTeTzip23MP8carQHrqXTEm5NfPJ88RJpqDHPDqcnpcBD5QYfQuUCiLqOzDVGaBgNDVJNMhd3M7ANC3ygVRSc775QWFkeNGBd-pyduNf-xiL6C0VFe9svgSh6Rur\" rel=\"nofollow\" target=\"_blank\">skaskela@kaskelalaw.com<\/a>)<br \/>Adrienne Bell, Esq.<br \/>(<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Yz-mkqArPbY6_388lTt1vckPLwtndub1orifuc6JLFPoK75Ww2-06YGizsdt6vxWxNU4EY2z6oAePmQ_BG0LmFrtUafpnTuG-4iC2LZk6vo=\" rel=\"nofollow\" target=\"_blank\">abell@kaskelalaw.com<\/a>)<br \/>18 Campus Blvd., Suite 100<br \/>Newtown Square, PA 19073<br \/>(484) 229 \u2013 0750<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dVFdqXDzQHW-XC9ZhWFXiOR-LZWR5LrtDrgFU5Sap7VVNxyFZwj2JoOgiU3v-wg9dOjER_jCM-ndU-_to7F4zrdAghWRPveyY1BKQCr2aB0=\" rel=\"nofollow\" target=\"_blank\">www.kaskelalaw.com<\/a><\/p>\n<p align=\"left\">This notice may constitute attorney advertising in certain jurisdictions.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMDAzMiM2ODU5ODQ4IzIwOTk5MzU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDNhYjZmZjMtMjVkMS00ZTAwLWE2NjktYjYyMTQ4YzY4ZDQxLTExMTE1MDYtMjAyNS0wNC0xMC1lbg==\/tiny\/Kaskela-Law.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PHILADELPHIA, April 10, 2025 (GLOBE NEWSWIRE) &#8212; Kaskela Law LLC announces that it is investigating Sage Therapeutics, Inc. (NASDAQ: SAGE) (\u201cSage\u201d) on behalf of the company\u2019s long-term investors. Click here for additional information: https:\/\/kaskelalaw.com\/case\/sage-therapeutics\/ Recently a securities fraud complaint was filed against Sage on behalf of certain investors who purchased or acquired shares of the company\u2019s stock between April 12, 2021 and July 23, 2024 (the \u201cClass Period\u201d). According to the complaint, during the Class Period, Sage and certain of the company\u2019s senior executive officers concealed adverse information and substantial risks associated with Sage\u2019s development of three pharmaceuticals: (i) zuranolone (SAGE-217\/BIIB125), a flagship drug, then under development in collaboration with affiliates of Biogen Inc. (together, \u201cBiogen\u201d), whose most lucrative potential &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SAGE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. (NASDAQ: SAGE) and Encourages Long-Term SAGE Investors to Contact the Firm&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-836075","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SAGE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. (NASDAQ: SAGE) and Encourages Long-Term SAGE Investors to Contact the Firm - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SAGE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. (NASDAQ: SAGE) and Encourages Long-Term SAGE Investors to Contact the Firm - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA, April 10, 2025 (GLOBE NEWSWIRE) &#8212; Kaskela Law LLC announces that it is investigating Sage Therapeutics, Inc. (NASDAQ: SAGE) (\u201cSage\u201d) on behalf of the company\u2019s long-term investors. Click here for additional information: https:\/\/kaskelalaw.com\/case\/sage-therapeutics\/ Recently a securities fraud complaint was filed against Sage on behalf of certain investors who purchased or acquired shares of the company\u2019s stock between April 12, 2021 and July 23, 2024 (the \u201cClass Period\u201d). According to the complaint, during the Class Period, Sage and certain of the company\u2019s senior executive officers concealed adverse information and substantial risks associated with Sage\u2019s development of three pharmaceuticals: (i) zuranolone (SAGE-217\/BIIB125), a flagship drug, then under development in collaboration with affiliates of Biogen Inc. (together, \u201cBiogen\u201d), whose most lucrative potential &hellip; Continue reading &quot;SAGE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. (NASDAQ: SAGE) and Encourages Long-Term SAGE Investors to Contact the Firm&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-10T13:22:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMDAzMiM2ODU5ODQ4IzIwOTk5MzU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SAGE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. (NASDAQ: SAGE) and Encourages Long-Term SAGE Investors to Contact the Firm\",\"datePublished\":\"2025-04-10T13:22:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\\\/\"},\"wordCount\":506,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMDAzMiM2ODU5ODQ4IzIwOTk5MzU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\\\/\",\"name\":\"SAGE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. (NASDAQ: SAGE) and Encourages Long-Term SAGE Investors to Contact the Firm - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMDAzMiM2ODU5ODQ4IzIwOTk5MzU=\",\"datePublished\":\"2025-04-10T13:22:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMDAzMiM2ODU5ODQ4IzIwOTk5MzU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMDAzMiM2ODU5ODQ4IzIwOTk5MzU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SAGE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. (NASDAQ: SAGE) and Encourages Long-Term SAGE Investors to Contact the Firm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SAGE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. (NASDAQ: SAGE) and Encourages Long-Term SAGE Investors to Contact the Firm - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\/","og_locale":"en_US","og_type":"article","og_title":"SAGE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. (NASDAQ: SAGE) and Encourages Long-Term SAGE Investors to Contact the Firm - Market Newsdesk","og_description":"PHILADELPHIA, April 10, 2025 (GLOBE NEWSWIRE) &#8212; Kaskela Law LLC announces that it is investigating Sage Therapeutics, Inc. (NASDAQ: SAGE) (\u201cSage\u201d) on behalf of the company\u2019s long-term investors. Click here for additional information: https:\/\/kaskelalaw.com\/case\/sage-therapeutics\/ Recently a securities fraud complaint was filed against Sage on behalf of certain investors who purchased or acquired shares of the company\u2019s stock between April 12, 2021 and July 23, 2024 (the \u201cClass Period\u201d). According to the complaint, during the Class Period, Sage and certain of the company\u2019s senior executive officers concealed adverse information and substantial risks associated with Sage\u2019s development of three pharmaceuticals: (i) zuranolone (SAGE-217\/BIIB125), a flagship drug, then under development in collaboration with affiliates of Biogen Inc. (together, \u201cBiogen\u201d), whose most lucrative potential &hellip; Continue reading \"SAGE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. (NASDAQ: SAGE) and Encourages Long-Term SAGE Investors to Contact the Firm\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-10T13:22:59+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMDAzMiM2ODU5ODQ4IzIwOTk5MzU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SAGE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. (NASDAQ: SAGE) and Encourages Long-Term SAGE Investors to Contact the Firm","datePublished":"2025-04-10T13:22:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\/"},"wordCount":506,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMDAzMiM2ODU5ODQ4IzIwOTk5MzU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\/","name":"SAGE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. (NASDAQ: SAGE) and Encourages Long-Term SAGE Investors to Contact the Firm - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMDAzMiM2ODU5ODQ4IzIwOTk5MzU=","datePublished":"2025-04-10T13:22:59+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMDAzMiM2ODU5ODQ4IzIwOTk5MzU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMDAzMiM2ODU5ODQ4IzIwOTk5MzU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-nasdaq-sage-and-encourages-long-term-sage-investors-to-contact-the-firm\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SAGE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. (NASDAQ: SAGE) and Encourages Long-Term SAGE Investors to Contact the Firm"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/836075","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=836075"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/836075\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=836075"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=836075"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=836075"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}